Loading…
Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study
Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The...
Saved in:
Published in: | BMC Infectious Diseases 2018, Vol.18 (1) |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Report |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 1 |
container_start_page | |
container_title | BMC Infectious Diseases |
container_volume | 18 |
creator | Oh, Dong Hyun Kim, Jung Ju Kim, Jinnam Seong, Hye Lee, Se Ju Kim, Yong Chan Kim, Eun Jin Jung, In Young Jeong, Woo Yong Jeong, Su Jin Ku, Nam Su Han, Sang Hoon Choi, Jun Yong Song, Young Goo Kim, June Myung |
description | Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia. |
doi_str_mv | 10.1186/s12879-018-2978-z |
format | report |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_IOV_A546399434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546399434</galeid><sourcerecordid>A546399434</sourcerecordid><originalsourceid>FETCH-gale_incontextgauss_IOV_A5463994343</originalsourceid><addsrcrecordid>eNqVjb1OxDAQhC0EEsfPA9BtSxGIk3BJ6NAJBBUFiPa056wvRj478m6A8GQ8HhxQ0FLNjDTzjVInOj_Tupmfsy6aus1y3WRFWzfZ-46a6arWWVGW1e4fv68OmJ_zXNdN0c7UxyJuBkyOY4BoQXoCstYZNNM2B7TGee8CYOhg7ScTBxrEdcSADB1ZF5y4F9ouEw4T2JhgQHEUhOHVSQ8bkt79UDIe2Wz3K0_wIDj0k48mGjN-4cZEX7JCI5Ro4_ASEBJJijyQ-f4wsY9JgGXspiO1Z9EzHf_qoTq9uX5c3GZr9LR0wcQg9CZrHJmXd_dPy6uLal62bVVW5X-6nzv1cvM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</creator><creatorcontrib>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</creatorcontrib><description>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-018-2978-z</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Bacteremia ; Care and treatment ; Chemical properties ; Dosage and administration ; Glycoproteins ; Nafcillin ; Staphylococcus aureus</subject><ispartof>BMC Infectious Diseases, 2018, Vol.18 (1)</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,4476,27902</link.rule.ids></links><search><creatorcontrib>Oh, Dong Hyun</creatorcontrib><creatorcontrib>Kim, Jung Ju</creatorcontrib><creatorcontrib>Kim, Jinnam</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Lee, Se Ju</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Kim, Eun Jin</creatorcontrib><creatorcontrib>Jung, In Young</creatorcontrib><creatorcontrib>Jeong, Woo Yong</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Han, Sang Hoon</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib><creatorcontrib>Kim, June Myung</creatorcontrib><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><title>BMC Infectious Diseases</title><description>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</description><subject>Bacteremia</subject><subject>Care and treatment</subject><subject>Chemical properties</subject><subject>Dosage and administration</subject><subject>Glycoproteins</subject><subject>Nafcillin</subject><subject>Staphylococcus aureus</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2018</creationdate><recordtype>report</recordtype><recordid>eNqVjb1OxDAQhC0EEsfPA9BtSxGIk3BJ6NAJBBUFiPa056wvRj478m6A8GQ8HhxQ0FLNjDTzjVInOj_Tupmfsy6aus1y3WRFWzfZ-46a6arWWVGW1e4fv68OmJ_zXNdN0c7UxyJuBkyOY4BoQXoCstYZNNM2B7TGee8CYOhg7ScTBxrEdcSADB1ZF5y4F9ouEw4T2JhgQHEUhOHVSQ8bkt79UDIe2Wz3K0_wIDj0k48mGjN-4cZEX7JCI5Ro4_ASEBJJijyQ-f4wsY9JgGXspiO1Z9EzHf_qoTq9uX5c3GZr9LR0wcQg9CZrHJmXd_dPy6uLal62bVVW5X-6nzv1cvM</recordid><startdate>20180130</startdate><enddate>20180130</enddate><creator>Oh, Dong Hyun</creator><creator>Kim, Jung Ju</creator><creator>Kim, Jinnam</creator><creator>Seong, Hye</creator><creator>Lee, Se Ju</creator><creator>Kim, Yong Chan</creator><creator>Kim, Eun Jin</creator><creator>Jung, In Young</creator><creator>Jeong, Woo Yong</creator><creator>Jeong, Su Jin</creator><creator>Ku, Nam Su</creator><creator>Han, Sang Hoon</creator><creator>Choi, Jun Yong</creator><creator>Song, Young Goo</creator><creator>Kim, June Myung</creator><general>BioMed Central Ltd</general><scope>IOV</scope></search><sort><creationdate>20180130</creationdate><title>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</title><author>Oh, Dong Hyun ; Kim, Jung Ju ; Kim, Jinnam ; Seong, Hye ; Lee, Se Ju ; Kim, Yong Chan ; Kim, Eun Jin ; Jung, In Young ; Jeong, Woo Yong ; Jeong, Su Jin ; Ku, Nam Su ; Han, Sang Hoon ; Choi, Jun Yong ; Song, Young Goo ; Kim, June Myung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_incontextgauss_IOV_A5463994343</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bacteremia</topic><topic>Care and treatment</topic><topic>Chemical properties</topic><topic>Dosage and administration</topic><topic>Glycoproteins</topic><topic>Nafcillin</topic><topic>Staphylococcus aureus</topic><toplevel>online_resources</toplevel><creatorcontrib>Oh, Dong Hyun</creatorcontrib><creatorcontrib>Kim, Jung Ju</creatorcontrib><creatorcontrib>Kim, Jinnam</creatorcontrib><creatorcontrib>Seong, Hye</creatorcontrib><creatorcontrib>Lee, Se Ju</creatorcontrib><creatorcontrib>Kim, Yong Chan</creatorcontrib><creatorcontrib>Kim, Eun Jin</creatorcontrib><creatorcontrib>Jung, In Young</creatorcontrib><creatorcontrib>Jeong, Woo Yong</creatorcontrib><creatorcontrib>Jeong, Su Jin</creatorcontrib><creatorcontrib>Ku, Nam Su</creatorcontrib><creatorcontrib>Han, Sang Hoon</creatorcontrib><creatorcontrib>Choi, Jun Yong</creatorcontrib><creatorcontrib>Song, Young Goo</creatorcontrib><creatorcontrib>Kim, June Myung</creatorcontrib><collection>Opposing Viewpoints Resource Center</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oh, Dong Hyun</au><au>Kim, Jung Ju</au><au>Kim, Jinnam</au><au>Seong, Hye</au><au>Lee, Se Ju</au><au>Kim, Yong Chan</au><au>Kim, Eun Jin</au><au>Jung, In Young</au><au>Jeong, Woo Yong</au><au>Jeong, Su Jin</au><au>Ku, Nam Su</au><au>Han, Sang Hoon</au><au>Choi, Jun Yong</au><au>Song, Young Goo</au><au>Kim, June Myung</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study</atitle><jtitle>BMC Infectious Diseases</jtitle><date>2018-01-30</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Studies have shown that the prognosis of the treatment of methicillin-susceptible S. aureus (MSSA) with glycopeptides is inferior compared to treatment with [beta]-lactam. However, there are only few studies comparing treatment with antistaphylococcal penicillin alone to glycopeptide treatment. The aim of this study was to compare the efficacy of nafcillin, an antistaphylococcal penicillin, with that of glycopeptides as a definitive therapy for MSSA bacteremia. A total of 188 patients with MSSA bacteremia were included in this study. The glycopeptide group had a higher rate of malignancy (28.6 vs. 60.8%, p < 0.001) and proportion of healthcare-associated infections (47.3 vs. 72.2%, p < 0.001) compared to the nafcillin group. The ratio of skin and soft tissue infections (30.0 vs. 16.7%, p = 0.037) and bone and joint infections (17.8 vs. 6.3%, p = 0.022), as well as levels of C-reactive protein (139.60 vs. 107.61 mg/dL, p = 0.022) were higher in the nafcillin group. All-cause 28-day mortality was significantly high in the glycopeptide group (7.7 vs. 20.6%, p = 0.013). In patients with MSSA bacteremia, all-cause 28-day mortality rate was higher in a group treated with glycopeptides than in a group treated with nafcillin. Therefore, the use of nafcillin should be considered as a definitive therapy for MSSA bacteremia.</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12879-018-2978-z</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2334 |
ispartof | BMC Infectious Diseases, 2018, Vol.18 (1) |
issn | 1471-2334 1471-2334 |
language | eng |
recordid | cdi_gale_incontextgauss_IOV_A546399434 |
source | Publicly Available Content Database; PubMed Central |
subjects | Bacteremia Care and treatment Chemical properties Dosage and administration Glycoproteins Nafcillin Staphylococcus aureus |
title | Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T18%3A18%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Comparison%20of%20the%20efficacy%20of%20nafcillin%20and%20glycopeptides%20as%20definitive%20therapy%20for%20patients%20with%20methicillin-susceptible%20Staphylococcus%20aureus%20bacteremia:%20a%20retrospective%20cohort%20study&rft.jtitle=BMC%20Infectious%20Diseases&rft.au=Oh,%20Dong%20Hyun&rft.date=2018-01-30&rft.volume=18&rft.issue=1&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-018-2978-z&rft_dat=%3Cgale%3EA546399434%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-gale_incontextgauss_IOV_A5463994343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A546399434&rfr_iscdi=true |